Carmustine: Promising Drug for Treatment of Glioma

Abstract

Background: The treatment for glioma has challenging and survival rate is not more than one year after diagnosis. Carmustine is a non-specific antineoplastic agent that belongs to the nitrosourea group of compounds (bischlo-roethyl nitrosourea) and has various mechanisms of tumor cytotoxicity. Main body: It can alkylate reactive sites on nucleoproteins as an alkylating agent, interfering with DNA and RNA synthesis and DNA repair. It can create interstrand crosslink’s in DNA, preventing DNA replication and transcription. Under physiological conditions, carmustine undergoes spontaneous nonenzymatic decomposition, releasing reactive intermediates with alkylating and carbamoylating activities, which are thought to be responsible for carmustine’s anticancer and cytotoxic properties. Human gliomas are the for the most part kind of tumor for brain. Gliomas can be treated with a variety of chemotherapeutics, but carmustine has recently emerged as a promising treatment option. Conclusion: The adoption of a nose-to-brain medication delivery method has several advantages over efforts that try to breach the blood-brain barrier. The focused strategy also lowers the risk of cardiovascular harm. A significant advantage of nose to brain administration is the relatively high patient compliance. Research into new chemotherapeutic compounds and treatment delivery technologies is crucial for present and future patients